Health insurance; cost-sharing payments for insulin and diabetes equipment and supplies.
Impact
The provisions of HB 760 will notably impact both individual and group health insurance policies, requiring that all carriers provide coverage for prescribed insulin drugs at the reduced cost-sharing level. Additionally, the bill mandates coverage for necessary diabetes equipment and supplies, thereby enhancing access to vital medical resources for those living with diabetes. This amendment is designed to support better health outcomes by making critical medications more affordable and accessible.
Summary
House Bill 760 aims to amend existing statutes regarding health insurance coverage for diabetes management. Specifically, it establishes a limit on cost-sharing payments for prescription insulin drugs to ensure that covered individuals do not pay more than $35 in aggregate per 30-day supply, irrespective of how many different types of insulin are prescribed. This legislation addresses the rising costs of insulin, which have become a significant financial burden for many patients managing diabetes.
Contention
While proponents argue that this bill is a necessary step towards reducing healthcare costs and improving the quality of life for individuals with diabetes, there are potential concerns regarding the financial implications for insurance providers. Critics of the bill may raise issues about the sustainability of such cost limitations and the potential for increased premiums as insurers adjust to the mandated cost-sharing caps. Furthermore, the bill establishes specific rules regarding health plans, leaving room for debates about the adequacy and availability of diabetes management services across different providers.
An Act to amend and reenact ยงยง 38.2-3407.15:5 and 38.2-3418.10 of the Code of Virginia, relating to health insurance; cost-sharing payments for insulin and diabetes equipment and supplies; limit.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.